Baxter Stock Slides After Q3 Sales Fall Short
Baxter (NYSE: BAX) shares dropped over 16% to $18.82 in early-morning trading after the company's third-quarter results failed to meet Wall Street's consensus sales forecast.
The company reported a net loss of $46 million, or 9¢ per share, on sales of $2.84 billion for the three months ended September. This represents a 132% decline in earnings from the same period last year, despite a 5% increase in sales.
Adjusted earnings per share were 69¢, beating Wall Street expectations by 9¢. However, sales fell short of estimates, with experts forecasting $2.88 billion in revenue.
The company's Medical Products & Therapies segment reported $1.33 billion in sales, marking a 1% decline.
No comment from the company is available at this time.
Author's summary: Baxter's Q3 sales disappoint investors.
More News
- Reversing course: Spotsylvania Board of Supervisors reduce recommended data center setbacks - Fredericksburg Free Press
- Thunder GM Sam Presti shares gut-wrenching Nikola Topic health news
- Russia Will Be Able to Send Cargo through Azerbaijan to Armenia - The Armenian Mirror-Spectator
- Shares of Navan Down 16% In Long-Awaited IPO Debut
- Armenian Bar Association Welcomes Seza Mikikian’s Judicial Appointment to the Los Angeles County Superior Court - The Armenian Mirror-Spectator
- Botanical Conservatory celebrates opening of new café
- Distorted narratives risk reversing South Caucasus peace progress [OPINION]
- Flau’jae Johnson Shuts Down Governor’s Call for Charlie Kirk Statue at LSU, Social Media Rides With Her
- Half of Illinois students reading at grade level, fewer in math under loosened standards
- Armenia’s Grisha Martirosyan among Operalia 2025 winners - The Armenian Mirror-Spectator